15 result(s) displayed (1 - 15 of 15):
Our oncology M&A list keeps growing. Sanofi-Aventis SA (NYSE:SNY), which is already on it, is acquiring the rights to sell an experimental cancer treatment developed by Merrimack Pharmaceuticals Inc. for up to $530 million. The Deal Pipeline (subscription required) has details on the transaction.The Merrimack deal comes after a setback...
Posted on October 1, 2009 2:06 PM
Shares of late-stage oncology companies Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Seattle Genetics Inc. (NASDAQ:SGEN) are trading higher as the companies are seen as possible acquisition targets. They have similar specializations to Medarex Inc. (NASDAQ:MEDX), which is being acquired by Bristol-Myers Squibb Co. (NYSE:BMY) for $2.4 billion.A Reuters story on...
Posted on July 24, 2009 12:07 PM
News of Celldex Therapeutics Inc. (NASDAQ:CLDX) acquiring CuraGen Corp. (NASDAQ:CRGN) for $94.5 million not only highlights a dealmaking trend we're tracking but signifies the need for a broader consolidation that could literally save lives.The acquisition of CuraGen will add a portfolio of oncology-focused, fully-owned antibodies to Celldex's precision-targeted immunotherapy platform....
Posted on May 29, 2009 12:30 PM
As Novartis AG (NYSE:NVS) finally uses some of the $5 billion it raised to acquire the generic injectables business of Austria's Ebewe Pharma GmbH, Pfizer Inc. (NYSE:PFE) is expanding in India.Pfizer entered into agreements with Claris Lifesciences Ltd. to commercialize sterile injectable medicines after the products are no longer...
Posted on May 20, 2009 4:18 PM
After about five months on the job, Sanofi-Aventis SA (NYSE:SNY) chief executive Chris Viehbacher is making his presence felt as the company reports profits are up about 16% and confirmed 2009 guidance.Viehbacher, on the hunt for acquisitions, cut 14 drugs in development from its pipeline of 65 -- including four...
Posted on April 29, 2009 2:53 PM
London-based pharma market intelligence report publisher URCH Publishing, which itself recently acquired pharma research firm Spectra Intelligence, is making predictions about who among the top 10 pharmas will follow in the footsteps of the sector's three biggest deals this year, with Bristol-Myers Squibb Co. (NYSE:BMY), Bayer AG and Novartis...
Posted on April 23, 2009 9:14 AM
Piramal Healthcare Ltd., the Indian generic drug maker, recently eyed by Sanofi-Aventis SA (NYSE:SNY) and possibly GlaxoSmithKline plc (NYSE:GSK), is looking to hire hundreds of people and acquire companies in Europe and North America. In December, Piramal spent $40 million on Minrad International Inc., a provider of generic inhalation anesthetics.Reuters...
Posted on April 22, 2009 8:14 AM
It hasn't even been two weeks since we last looked at what was on the dealmaking plate for Laurence Debroux, the CFO that's now also strategy chief at Sanofi-Aventis SA (NYSE:SNY), and the Paris firm has announced another two deals valued at over $1 billion.The Deal Pipeline shows Sanofi...
Posted on April 15, 2009 3:12 PM
While hopes of a Bristol-Myers Squibb Co. (NYSE:BMY) sale dwindle, the New York pharma giant is looking at other avenues to hedge against its blockbuster drugs facing generic competition. Bristol agreed with Japan's Otsuka Pharmaceutical Co. to extend a sales agreement for schizophrenia drug Abilify from November 2012 to April...
Posted on April 6, 2009 9:03 AM
When CFO Laurence Debroux changed her role to include dealmaking at Sanofi-Aventis SA (NYSE:SNY), she knew her schedule would get pretty busy. A few weeks before Debroux (pictured) became the French pharma giant's chief strategy officer, CEO Chris Viehbacher made it clear the company was seeking acquisitions -- of a...
Posted on April 2, 2009 4:34 PM
GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty has said megamergers are a bad idea and that he likes being in consumer products (translation: look for bolt-on deals). More recently, at the Cowen & Co. healthcare conference in Boston, Witty (pictured) said Glaxo plans to shift money from its pharmaceuticals...
Posted on March 18, 2009 2:34 PM
The deal may not be quite as big, but Pfizer Inc. (NYSE:PFE) recognizes the importance of the generic drug market.Following Sanofi-Aventis SA's $1.9 billion acquisition of Czech drug maker Zentiva NV -- making it the world's No. 11 maker of generic medicines, -- Pfizer signed a deal with India's Aurobindo...
Posted on March 3, 2009 4:22 PM
Sanofi-Aventis SA has created a chief strategy officer position as it looks to reduce its reliance on blockbuster drugs. CFO Laurence Debroux (pictured) will take on the new role and will focus on better coordinating partnerships, M&A and other development projects with corporate strategy. She will report to chief executive...
Posted on February 12, 2009 9:59 AM
With cash on their balance sheets, blockbuster drugs headed off-patent and other product gaps that need filling, healthcare giants are on the acquisition trail. Chris Viehbacher, CEO of France's Sanofi-Aventis, said he plans to make acquisitions and wants to diversify the group's product range, according to a Reuters report. Over-the-counter...
Posted on February 2, 2009 1:31 PM
One of the year's major mergers was officially consummated in August, and the first big development was the naming of a new head of business development. Olivier Jacquesson now has that job at Sanofi-Aventis, serving on the management committee and reporting to CEO Jean-François Dehecq. The manner of Jacquesson's...
Posted on December 15, 2004 10:13 AM
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
